Jayne M. Munger

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Cooley advised Core Scientific (NASDAQ: CORZ), a leader in digital infrastructure for bitcoin mining and high-performance computing, on its $625 million aggregate principal of 0.00% convertible senior notes due 2031, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes.

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Cooley advised Beam Therapeutics, a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines, on its agreement with Verve Therapeutics to sell its opt-in rights to co-develop and co-commercialize base-editing programs for cardiovascular disease to Eli Lilly and Company.